Results 31 to 40 of about 650,104 (308)

The biology of castration-resistant prostate cancer [PDF]

Current Problems in Cancer, 2015
Prostate cancer is one of the most commonly diagnosed cancers and the second leading cause of cancer death in men in the United States. Although there are recently approved therapeutic options for men with advanced and metastatic disease, the unfortunate reality is that advanced prostate cancer is inevitably fatal. Hormonal androgen deprivation therapy
Fei, Lian, Nitya V, Sharma, Josue D, Moran, Carlos S, Moreno   +3 more
openaire   +2 more sources

Autocrine activation of MAPK signaling mediates intrinsic tolerance to androgen deprivation in LY6D prostate cancer cells

Cell Reports, 2023
Summary: The emergence of castration-resistant prostate cancer remains an area of unmet clinical need. We recently identified a subpopulation of normal prostate progenitor cells, characterized by an intrinsic resistance to androgen deprivation and ...
Ivana Steiner, Teresita del N.J. Flores-Tellez, Renaud Mevel, Amin Ali, Pengbo Wang, Pieta Schofield, Caron Behan, Nicholas Forsythe, Garry Ashton, Catherine Taylor, Ian G. Mills, Pedro Oliveira, Simon S. McDade, Dietmar M. Zaiss, Ananya Choudhury, Georges Lacaud, Esther Baena   +16 more
doaj   +1 more source

Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience

, 2023
Objective: Lutetium-177 prostate-specific membrane antigen-617 is a novel alternative therapeutic option in metastatic castration-resistant prostate cancer, especially useful for patients who do not respond to standard therapy methods.
Maman, Adem, Adem Maman
core   +1 more source

Temporal patterns of inflammatory gene expression in local tissues after banding or burdizzo castration in cattle [PDF]

, 2009
peer-reviewedBackground: Castration of male cattle has been shown to elicit inflammatory reactions and acute inflammation is initiated and sustained by the participation of cytokines.
Gath Vivian, Pang, Wanyong, Earley Bernadette, Sweeney, Torres, Sweeney Torres, Earley, Bernadette, Crowe Mark A, Gath, Vivian, Pang Wanyong, Crowe, Mark A   +9 more
core   +1 more source

Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer

Istanbul Medical Journal, 2022
Introduction:For metastatic prostate cancer (PC), androgen deprivation therapy (ADT) is the primary treatment option. Most patients develop resistance, after an initial response to treatment. This study aimed to evaluate real-life data of first-line docetaxel treatment for metastatic castration-resistant prostate cancer (mCRPC) and analyzed whether the
İlkay Gültürk, Gülçin Şahingöz Erdal, Gülru Birce Sönmezoz, Mesut Yılmaz, Seher Yıldız Tacar, Aykut Özmen, Deniz Tataroğlu Özyükseler, Özgecan Dulgar, İbrahim Çil, Deniz Tural   +9 more
openaire   +2 more sources

Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy

IJU Case Reports, 2022
Introduction Treatment strategy for castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy has not been established.
Takahiro Komori, Takeo Kosaka, Keitaro Watanabe, Tomoki Tanaka, Yota Yasumizu, Hiroshi Hongo, Shuji Mikami, Toshio Ohashi, Mototsugu Oya   +8 more
doaj   +1 more source

Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations

Journal of the Korean Society of Radiology, 2023
In prostate cancer, the bone is the most common site of metastasis, and it is essential to evaluate metastatic bone lesions to assess the tumor burden and treatment response.
Ji Sung Jang, Amy Junghyun Lee, Kye Jin Park, Kyung Won Kim, Hyo Jung Park   +4 more
doaj   +1 more source

Drug–Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer

Pharmaceutics, 2022
Ipatasertib is a selective, small molecule Akt inhibitor that is currently being developed for the treatment of metastatic castration-resistant prostate cancer. Darolutamide is an androgen receptor (AR) inhibitor that is approved for the treatment of non-
Dhruvitkumar S. Sutaria, Grozdana Rasuo, Adam Harris, Ryan Johnson, Dale Miles, Jorge Daniel Gallo, Rucha Sane   +6 more
doaj   +1 more source

Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)

BMC Urology, 2022
Background Prostate cancer (PCa) is one of the most diagnosed cancers in the world. PCa inevitably progresses to castration-resistant prostate cancer (CRPC) after androgen deprivation therapy treatment, and castration-resistant state means a shorter ...
Yan Li, Hui Shi, Zhenjun Zhao, Minghui Xu   +3 more
doaj   +1 more source

Prostate-Specific Antigen and Time to PSA Nadir as Prognostic Significance in Castration-Resistant Prostate Cancer

Folia Medica Indonesiana, 2022
Highlight: • Assessing the survival rate in castration-resistant prostate cancer was descriptived. • PSA level between survivor and non survivor was significant but not for PSA nadir level, TTN and TTC.
Firmantya Hadi Pranata, Wahjoe Djatisoesanto, Doddy Moesbadianto Soebadi   +2 more
doaj   +1 more source